Vasoactive Intestinal Peptide Protects Salivary Glands against Structural Injury and Secretory Dysfunction via IL-17A and AQP5 Regulation in a Model of Sjögren Syndrome
Author：Li C, Zhu F., Wu B., Wang Y. 《Neuroimmunomodulation》
ABSTRACTS
Objective: Sjögren syndrome (SS) is an autoimmune disease involving exocrine glands. Currently, drugs that can improve both abnormal immunity and exocrine gland function are needed. The study aimed to investigate the effect and mechanism of vasoactive intestinal peptide (VIP) on the immune response and exocrine gland function in SS.
Conclusions: Using a model of SS, we found that VIP could not only modulate the immune response but also affect exocrine gland function, and that these therapeutic effects were associated with IL-17A and AQP5 regulation.
KEY WORDS
SCREENSHOT
RELATED PRODUCTS
The mice in the pre-vention group were given 1.5 nmol VIP (synthesized by China Peptides, Shanghai, China; purity 98.38%)
CHAINING
https://www.karger.com/Article/Abstract/486859
コメント